GoodRx matches Novo's cash price for the Wegovy pill

GoodRx said on January 5, 2026, that it is now offering the newly FDA-approved Wegovy pill (oral semaglutide) at a cash price of $149 per month for the two lowest doses, matching the price Novo Nordisk itself set at launch ^[1]. The pill is available through more than 70,000 pharmacies nationwide, and GoodRx says it will soon let people use its GoodRx for Weight Loss telehealth service to check eligibility and get a prescription for the pill or other GLP-1 treatments if a provider decides it's appropriate ^[1].

The $149 price applies to the 1.5 mg and 4 mg doses only through April 15, 2026. After that date, the 4 mg dose rises to $199 per month. The two higher doses, 9 mg and 25 mg, cost $299 per month on GoodRx ^[1]. Wegovy's 25 mg dose is currently the only FDA-approved oral GLP-1 pill for weight loss, and it also carries an approval for reducing the risk of major cardiovascular events ^[2].

GoodRx CEO Wendy Barnes said the company wants to combine "transparent cash pricing with streamlined access to care and broad pharmacy availability" as oral GLP-1 options expand ^[1]. The company, which says it has helped Americans save more than $85 billion since 2011 and is used by nearly 30 million consumers a year, framed the launch pricing as a model for how drugmakers can roll out new cash-pay programs quickly through its pharmacy network ^[1].

The GoodRx move came about a month before a separate government-linked effort. On February 5, 2026, the TrumpRx platform launched, built on "most favored nation" pricing deals the Trump administration struck with drugmakers including Novo Nordisk and Eli Lilly ^[2]. Reported TrumpRx figures include cutting Wegovy's monthly cost from $1,350 to $350 and Zepbound's from $1,086 to $346, with an oral GLP-1 pill listed at an initial price of $150 ^[2]. TrumpRx does not sell drugs directly; it routes shoppers to manufacturer websites, and it requires cash payment, meaning insurance is not accepted there ^[2].

Why it matters for patients

For people without insurance coverage for weight-loss drugs, or who face high copays, a documented $149-a-month cash price for two Wegovy pill doses is a specific, near-term number to compare against other options, rather than a vague promise of future savings ^[1]. The price is time-limited for the 4 mg dose, rising to $199 after April 15, 2026, so the deal available today is not the deal available later in the year ^[1].

Insured patients should keep in mind that cash prices like GoodRx's or TrumpRx's are not always the cheapest route. Analysts have noted that people with insurance coverage, or access to a cheaper generic, could end up paying more by using a cash-only platform than by filling a prescription through their normal pharmacy benefit ^[2]. Both GoodRx's $149 offer and TrumpRx's $350 figure for injectable Wegovy are cash prices, and TrumpRx does not accept health insurance at all ^[2].

The emergence of two competing discount channels for the same drug, GoodRx and TrumpRx, also means the